Lung Cancer

1. What This Condition Is

Lung cancer is a malignancy that originates in the tissue of the lungs. The two primary types are non-small cell lung cancer (NSCLC), which accounts for approximately 85% of cases and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and small cell lung cancer (SCLC), which is more aggressive and closely associated with smoking. Symptoms include a persistent cough, blood in sputum, chest pain, shortness of breath, hoarseness, and unintentional weight loss. Lung cancer is among the most lethal malignancies because it is often diagnosed at an advanced stage.

Veterans have significantly elevated rates of lung cancer due to multiple overlapping exposure histories. Lung cancer is a recognized presumptive condition for veterans exposed to Agent Orange and other tactical herbicides under 38 CFR 3.309(e) as amended by the PACT Act of 2022 (Public Law 117-168). Veterans who served in Vietnam, the Korean Demilitarized Zone during the qualifying period, or other herbicide-exposure locations, and who develop primary lung cancer, are entitled to presumptive service connection without proving a direct medical link between exposure and diagnosis.

The PACT Act of 2022 additionally expanded presumptive service connection for veterans exposed to burn pits, airborne hazards, and other toxic exposures at covered locations during post-9/11 service. Respiratory cancers — including lung cancer — are among the conditions covered under the PACT Act airborne hazards presumptive. Veterans who served at locations covered under the PACT Act and who develop lung cancer may claim service connection under that authority.

Asbestos exposure during military service — particularly in Navy veterans who worked in shipyards, engine rooms, and boiler rooms — is another well-documented service-connected cause of mesothelioma and lung cancer. While asbestos-related lung cancer is not a listed presumptive, direct service connection through a nexus opinion is well-supported for veterans with documented asbestos exposure.

2. VA Rating Criteria

Lung cancer is rated under 38 CFR § 4.97, Diagnostic Code 6819 (Neoplasms, Malignant, Any Specified Part of Respiratory System, Exclusive of Skin).

Active disease or treatment: A 100% rating applies during any period of active lung cancer or during any treatment (surgery, chemotherapy, radiation, immunotherapy, targeted therapy, or any combination thereof).

Post-treatment: Following the completion of a defined treatment course, the 100% rating continues for a minimum of six months. After that period, the VA schedules a rating examination to assess residual disability.

Residual ratings: After treatment, the veteran is rated based on residual pulmonary function and respiratory impairment. Residual pulmonary disability is rated under the respiratory schedule based on:

• Pulmonary function testing (FEV1, FVC, DLCO)
• Exercise testing and functional capacity
• The presence and severity of dyspnea on exertion

Under DC 6600 (Bronchitis, Chronic) and DC 6844 (Pulmonary Fibrosis and Emphysema with Pulmonary Dysfunction) and related respiratory codes, residual lung disability is rated based on the degree of measured impairment:

Other residual conditions from lung cancer treatment — peripheral neuropathy from chemotherapy, cardiac toxicity from certain chemotherapy agents, radiation pneumonitis, and radiation fibrosis — are each separately ratable under the applicable diagnostic codes.

3. What to Expect at Your C&P Exam

For active disease or treatment, the examiner will confirm the diagnosis, stage, and treatment status. The 100% rating is assigned without further functional assessment during active disease and treatment.

For a residual exam after treatment, the examiner will review pulmonary function test results and assess your current exercise capacity. Be prepared to describe your breathing at rest, with light exertion (walking on flat ground), and with more demanding activity. Describe whether you require supplemental oxygen, use inhalers or bronchodilators, and whether you have had pulmonary rehabilitation.

Describe the functional limitations from any surgery: if you had a lobectomy, pneumonectomy, or wedge resection, describe your reduced respiratory capacity and how it limits your daily activities, work capacity, and exercise tolerance.

Also describe chemotherapy-related residuals: neuropathy in hands and feet, fatigue, cognitive effects, and any cardiac changes from treatment. Each of these residuals may be separately ratable and should be documented.

4. Evidence You Need to Win

Diagnosis: Pathology report confirming lung cancer histology and stage. Imaging (CT scan, PET scan) documenting tumor location, size, and extent. All oncology records including surgical operative reports, chemotherapy records, and radiation treatment records.

Service Record Evidence (Presumptive Claims): For Agent Orange / Vietnam veterans: DD-214 or service records confirming qualifying service. For PACT Act claims: documentation of service at covered locations where airborne hazards or burn pit exposure occurred. For Navy asbestos exposure: service records confirming ship assignment and duty in areas with known asbestos exposure.

No Nexus Letter Required for Presumptive Claims: If the Agent Orange or PACT Act presumptive applies, a physician nexus is not required. Document the diagnosis and qualifying service and file.

Nexus Letter (Non-Presumptive Direct Claims): For veterans whose lung cancer claim is based on direct service connection — such as occupational carcinogen exposure, asbestos, or radiation — a pulmonologist or oncologist must provide a nexus letter stating "at least as likely as not" with a rationale.

DBQ Form: The Respiratory Conditions DBQ or the malignant neoplasm DBQ appropriate for lung cancer. Your treating pulmonologist or oncologist should complete this form with diagnosis, stage, treatment history, current pulmonary function, and residual assessment.

Pulmonary Function Testing: Post-treatment PFT results documenting FEV1, FVC, and DLCO. These are the objective data the examiner uses to assign the residual respiratory rating.

Personal Statement: Describe the functional impact of active disease, treatment, and residuals. Describe how shortness of breath limits your activities, how fatigue affects your daily function, and what you can no longer do because of lung disease.

Buddy Statements (VA Form 21-10210): Observers who can describe your exercise intolerance, your oxygen requirements, or the functional impact of treatment provide lay corroboration.

5. Secondary Conditions to Consider

Peripheral Neuropathy: Platinum-based chemotherapy agents used for lung cancer (cisplatin, carboplatin) cause peripheral neuropathy. Secondary neuropathy from treatment of service-connected lung cancer is ratable.

Cardiac Toxicity: Certain chemotherapy agents, particularly anthracyclines and targeted therapies, cause cardiomyopathy. Secondary cardiac conditions from lung cancer treatment may be ratable.

Radiation Pneumonitis and Fibrosis: Radiation therapy to the chest can cause acute pneumonitis and, over time, pulmonary fibrosis that restricts respiratory capacity. These treatment residuals are ratable under the respiratory schedule.

Depression and Anxiety: A lung cancer diagnosis produces significant psychological burden. Secondary mental health conditions are ratable under 38 CFR 3.310.

Sleep Apnea: Respiratory compromise from reduced lung volume after surgery or from pulmonary fibrosis can worsen or precipitate obstructive sleep apnea. Secondary OSA may be ratable.

Chronic Pain: Thoracic surgical pain, chest wall pain from radiation, and tumor-related pain may require separate evaluation if they produce functional impairment beyond what the primary lung cancer rating captures.

6. Common Mistakes That Kill Claims

Not filing immediately on diagnosis. The 100% rating during active disease is tied to the date of claim. File immediately on diagnosis — not after surgery, not after the first chemotherapy cycle. File the day you receive the diagnosis.

Not knowing the PACT Act expanded the presumptive. Post-9/11 veterans who served near burn pits and who develop lung cancer are entitled to presumptive service connection under the PACT Act of 2022. Many of these veterans were not aware the law passed or that their condition qualifies. File.

Failing to claim pulmonary residuals separately. After the 100% active disease rating ends, veterans who do not have current pulmonary function testing documenting impairment may receive a 0% residual rating. Obtain PFTs before the residual exam.

Not claiming chemotherapy neuropathy. Peripheral neuropathy from platinum-based chemotherapy is a common, measurable, and ratable residual. Veterans who have numbness and tingling in their hands and feet after treatment and never file for neuropathy are leaving compensation behind.

Missing the asbestos pathway for Navy veterans. Veterans who served in shipyards or aboard ships with documented asbestos use and who develop lung cancer should pursue direct service connection through a nexus letter — not just the presumptive — if the Agent Orange or PACT Act presumptive does not apply to their service dates and locations.

7. FWD Assist Resources

The following FWD Assist HQ books are directly relevant to a lung cancer claim:

• Agent Orange: The Complete Vietnam Veterans Claims Guide — covers the expanded presumptive list including lung cancer under PACT Act, qualifying service locations, and how to file
• The PACT Act Playbook — covers PACT Act presumptive coverage for post-9/11 veterans exposed to burn pits and airborne hazards, including lung and respiratory cancers
• C&P Exam Prep Guide — covers what to expect at a cancer residual exam and how to document pulmonary function limitations for the respiratory rating formula
• Secondary Conditions Guide — covers chemotherapy neuropathy, cardiac toxicity, and mental health secondary chains from service-connected lung cancer

All titles are available at fwdassisthq.com.

8. Get Help Without a Claim Shark

Free, accredited help is available through Veterans Service Organizations including the DAV, VFW, American Legion, and AMVETS. County Veterans Service Officers (CVSOs) file and manage claims at no cost.

Charging upfront fees to assist with a VA claim is illegal under 38 U.S.C. § 5905. VA-accredited attorneys and claims agents may charge fees only after an initial VA decision, capped at 20% of past-due benefits under 38 U.S.C. § 5904. No legitimate representative asks for money before your first decision.

Verify accreditation at va.gov/ogc/accreditation.asp.